老年近肾腹主动脉瘤开放修复与开窗腔内修复的30天死亡率相当
本研究基于ACS-NSQIP数据库,对≥70岁接受择期近肾腹主动脉瘤修复的患者进行1:1倾向性匹配,比较开放手术(OSR)与开窗腔内修复(FEVAR)的30天结局。最终纳入136对患者,两组30天死亡率无显著差异(4.4% vs 3.7%),但OSR组肺部并发症(19.1% vs 3.7%)和肾脏并发症(8.1% vs 2.2%)显著更高。结论认为FEVAR仍应作为老年近肾腹主动脉瘤的一线治疗,但OSR可作为解剖不适合FEVAR患者的选择。
要点
- 老年近肾腹主动脉瘤开放手术与开窗腔内修复的30天死亡率无显著差异。
- 开放手术的肺部并发症和肾脏并发症发生率显著高于开窗腔内修复。
- 开窗腔内修复仍应作为老年近肾腹主动脉瘤的一线治疗,开放手术可作为解剖不适合者的替代选择。
核心结论
- 在≥70岁近肾腹主动脉瘤患者中,开放手术与开窗腔内修复的30天死亡率无显著差异,但开放手术的肺部及肾脏并发症更高。
- 开窗腔内修复仍应作为老年近肾腹主动脉瘤的一线治疗,开放手术可作为解剖不适合开窗腔内修复患者的可接受替代。
研究设计与样本
- 回顾性队列研究,使用美国外科医师学会国家手术质量改进计划(ACS-NSQIP)2012至2018年靶向EVAR和AAA数据库。
- 纳入≥70岁接受择期非破裂近肾腹主动脉瘤修复的患者,排除开放手术中行腹腔干以上阻断或同期肾/内脏血管重建者。
- 采用1:1倾向性匹配算法,按术前临床和人口学特征、手术指征及动脉瘤范围匹配开放手术与开窗腔内修复患者。
- 最终分析纳入136例开放手术患者和136例开窗腔内修复患者。
临床怎么用
- 对于≥70岁近肾腹主动脉瘤患者,开窗腔内修复应作为一线治疗选择。
- 对于解剖不适合开窗腔内修复的老年患者,开放手术可作为可接受的替代方案,但需注意肺部及肾脏并发症风险较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Endovascular repair of juxtarenal abdominal aortic aneurysms (JAAAs) with fenestrated grafts (fenestrated endovascular aneurysm repair [FEVAR]) has been reported to decrease operative mortality and morbidity compared with open surgical repair (OSR). However, previous comparisons of OSR and FEVAR have not necessarily included patients with comparable clinical profiles and aneurysm extent. Although FEVAR has often been chosen as the first-line therapy for high-risk patients such as the elderly, many patients will not have anatomy favorable for FEVAR. At present, a paucity of data has examined the operative outcomes of OSR in elderly patients for JAAAs relative to FEVAR. Therefore, we chose to perform a propensity-matched comparison of OSR and FEVAR for JAAA repair in patients aged ≥70 years. METHODS: Patients aged ≥70 years who had undergone elective nonruptured JAAA repairs from 2012 to 2018 were identified in the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) targeted endovascular aneurysm repair (EVAR) and AAA databases. Patients who had undergone FEVAR were identified in the targeted EVAR database as those who had received the Cook Zenith Fenestrated endograft (Cook Medical, Bloomington, Ind). Because our study specifically examined JAAAs, those patients who had undergone OSR with supraceliac proximal clamping or concomitant renal/visceral revascularization were excluded. A 1:1 propensity-match algorithm matched the OSR and FEVAR patients by preoperative clinical and demographic characteristics, operative indications, and aneurysm extent. The 30-day outcomes, including mortality, major adverse cardiovascular events, and pulmonary and renal complications, were compared between the propensity-matched OSR and FEVAR groups. RESULTS: A 1:1 propensity match was achieved, and the final analysis included 136 OSR patients and 136 FEVAR patients. No significant differences were found in 30-day mortality (4.4% vs 3.7%; odds ratio [OR], 1.21; 95% confidence interval [CI], 0.36-4.06; P = .759) between the OSR and FEVAR groups. OSR was associated with a higher incidence of major adverse cardiovascular events compared with FEVAR; however, the trend was not statistically significant (8.1% vs 3.7%; OR, 2.31; 95% CI, 0.78-6.82; P = .131). Compared with FEVAR, the OSR group had significantly greater rates of pulmonary complications (19.1% vs 3.7%; OR, 6.19; 95% CI, 2.30-16.67; P < .001) and renal complications (8.1% vs 2.2%; OR, 3.90; 95% CI, 1.06-14.31; P = .040). CONCLUSIONS: In the samples assessed in the present study, the results with OSR of JAAAs in the elderly did not differ from those of FEVAR with respect to 30-day mortality despite a greater incidence of pulmonary and renal complications. Although FEVAR should remain the first-line therapy for JAAAs in elderly patients, OSR might be an acceptable alternative for select patients with anatomy unfavorable for FEVAR.
引用
- Rosenfeld ES, Macsata RA, Lala S, et al. Open surgical repair of juxtarenal abdominal aortic aneurysms in the elderly is not associated with increased thirty-day mortality compared with fenestrated endovascular grafting. J Vasc Surg. 2020. PMID: 32919026. doi:10.1016/j.jvs.2020.08.121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。